Overview

EPX-100 (Clemizole Hydrochloride) as Add-on Therapy to Control Convulsive Seizures in Patients With Dravet Syndrome

Status:
Recruiting
Trial end date:
2023-09-01
Target enrollment:
Participant gender:
Summary
The purpose of this study is to compare the efficacy of EPX-100 against placebo as adjunctive therapy in 60 patients with Dravet Syndrome.
Phase:
Phase 2
Details
Lead Sponsor:
Epygenix
Collaborator:
GreenLight Clinical PTY LTD